Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
Nature Medicine1999Vol. 5(10), pp. 1135–1142
Citations Over TimeTop 1% of 1999 papers
Stéphane Heymans, Aernout Luttun, Dieter Nuyens, Gregor Theilmeier, Esther E. Creemers, Lieve Moons, G.D. Dyspersin, Jack P.M. Cleutjens, M. Shipley, Anne Angellilo, Moshe Levi, O. Nüβe, Andrew H. Baker, Eli Keshet, Florea Lupu, J‐M. Herbert, Jos F.M. Smits, Steven D. Shapiro, Myriam Baes, M. Borgers, D Collen, Mat J.A.P. Daemen, Peter Carmeliet
Related Papers
- → Urokinase-type plasminogen activator is activated in stratum corneum after barrier disruption(2003)27 cited
- → Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism(2007)31 cited
- → Pro-urokinase up-regulates the expression of urokinase-type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells(2007)3 cited
- → Induction of Synthesis of Plasminogen Activator Inhibitor Type-1 byTissue-Type Plasminogen Activator in Human Hepatic and Endothelial Cells(1990)37 cited
- → Increased urokinase activity to antigen ratio in human renal‐cell carcinoma(1985)19 cited